Full title:A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Malignancies
Age: 18+
Phase: 1
Locations:
- London – The Royal Marsden
Brief summary:
The treatment is a drug known as NB003 and will be given to patient with GIST or other advanced solid tumours to explore the safety and effectiveness of it as a treatment.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
